Does TSLP Inhibition Signal The Next Wave Of Respiratory Biologics?
By Mercedes Fleming, Ph.D., senior business analyst, Lifescience Dynamics
Thymic stromal lymphopoietin (TSLP) inhibition has firmly established itself as an upstream strategy in respiratory disease. With Tezspire (tezepelumab), developed by AstraZeneca and Amgen, now approved in both asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) (U.S. and EU), TSLP blockade has validated the concept that targeting an epithelial “master switch” can modulate multiple downstream inflammatory pathways. By acting upstream of IL-4, IL-5, and IL-13 signalling, TSLP inhibition offers efficacy beyond traditional eosinophilic or Type 2-high populations, positioning the class as broadly applicable across heterogeneous respiratory phenotypes. This breadth of activity also creates a distinct strategic advantage, enabling therapies to be positioned across wider patient populations without strict biomarker segmentation.
Long-Acting Therapies Shift The Competitive Focus
The year ahead will test how far this upstream paradigm can expand, particularly as long-acting and next-generation approaches read out and move through clinical development. In asthma, long-acting TSLP programs are now central to the competitive narrative. Upstream Bio’s long-acting TSLP receptor antibody, verekitug, recently reported Phase 2 VALIANT data, demonstrating a 56% placebo-adjusted reduction in annualized asthma exacerbation rate (AAER) at Q12W dosing, reinforcing the view among many clinicians that reductions of around 50% represent a clinically meaningful benchmark in this setting. Importantly, however, discussion in the field increasingly emphasizes that cross-trial comparisons are imperfect and that dosing convenience may influence prescribing decisions as much as modest differences in efficacy. As a result, future differentiation in this class may depend less on incremental efficacy gains and more on how effectively therapies reduce treatment burden and integrate into real-world care pathways.
This growing focus on durability and convenience is shaping the next phase of competition in severe asthma. Uniquity Bio will also report solrikitug Phase 2 RAINIER data in asthma in the first half of 2026. Meanwhile, Generate Bio initiated a Phase 3 trial of GB-095 in late 2025, and GSK’s long-acting TSLP program continues in Phase 2 development. Collectively, these programs are exploring whether Q12W or even Q24W regimens can reduce injection burden relative to existing Q4W biologics without compromising efficacy. If successful, such profiles could support life cycle differentiation and potentially expand biologic use into patient segments prioritizing convenience. For drug developers, achieving extended dosing intervals may represent one of the most tangible ways to differentiate within an increasingly crowded landscape, particularly if paired with comparable efficacy and safety. Mechanistic differentiation may also become increasingly relevant. Verekitug, which targets the TSLP receptor, contrasts with Tezspire’s ligand-based approach and may enable more complete pathway suppression. This distinction could translate into more durable pharmacologic activity and support extended dosing intervals, suggesting that differences in target engagement may ultimately drive both clinical performance and commercial differentiation.
Expanding Beyond Asthma
Verekitug’s development program has already demonstrated activity beyond asthma, with positive Phase 2 VIBRANT data in CRSwNP reported in September 2025, supporting the breadth of upstream TSLP receptor inhibition across airway inflammatory diseases. Attention now turns to chronic obstructive pulmonary disease (COPD), where verekitug’s Phase 2b VENTURE study in moderate to severe disease is expected to read out in the first half of 2026, alongside solrikitug’s Phase 2 ZION data anticipated in the second half of 2026. COPD remains a high-unmet-need, multibillion-dollar market with historically limited biologic success. Positive data would meaningfully broaden the TSLP opportunity and reinforce the hypothesis that upstream epithelial biology can address exacerbation-driven disease across phenotypes. Success in COPD could represent an advancement in the commercial potential of the class. Unlike asthma, where multiple biologics already compete, COPD remains relatively underpenetrated by biologic therapies. Demonstrating efficacy in this setting would not only validate upstream inhibition but could also position TSLP therapies as foundational treatments across both asthma and COPD, significantly expanding their addressable market.
Next-Generation Approaches And New Modalities
Combination biology is also advancing with Sanofi and Regeneron’s lunsekimig, a bispecific targeting TSLP and IL-13, set to report Phase 2 AIRCULES data in asthma in the first half of 2026. This approach aims to combine upstream breadth with downstream pathway specificity within a single molecule. Pfizer’s triple-target candidate directed against TSLP, IL-13, and IL-4 is progressing in asthma, with Phase 3 development in COPD initiated earlier in 2026. These programs will help determine whether broader pathway coverage delivers incremental clinical benefit or whether established monotherapies remain sufficient for most patients. For companies pursuing these approaches, the key challenge will be demonstrating clear and clinically meaningful improvements over existing therapies. Without a material benefit in efficacy or patient outcomes, increased molecular complexity alone may not justify differentiation, particularly in a market where convenience and safety are already major decision drivers.
In parallel, inhaled TSLP inhibition may represent a step-change in delivery. AstraZeneca’s inhaled AZD8630 will report Phase 2 LEVANTE data in asthma in the first half of 2026, exploring localized upstream blockade at the airway epithelium. If inhaled delivery demonstrates meaningful exacerbation reduction with favorable tolerability, it could enable earlier-line use and offer an alternative to injectable biologics. More importantly, it could shift how biologics are positioned within treatment algorithms, moving upstream therapies earlier in the disease course and expanding use beyond severe, biomarker-specific populations. This may allow companies to compete not only with other biologics but with established inhaled maintenance therapies, effectively redefining the treatment paradigm.
Seizing Competitive Edge In 2026 And Beyond
Taken together, 2026 is shaping up as a defining year for TSLP-directed therapies, but success will likely be determined by clear, practical differentiation rather than class expansion alone. From a prescriber perspective, priorities will center on consistent efficacy across phenotypes, including low-eosinophil populations, meaningful steroid-sparing outcomes, and clear positioning versus established IL-5 and IL-4R therapies, with durability and reduced dosing burden playing an increasingly important role in treatment decisions. Patient expectations will focus on tangible improvements over current care, including fewer injections, convenient or at-home administration, and rapid, sustained symptom control, alongside access and reimbursement considerations that influence real-world uptake.
Within this landscape, competitors will need to deliver differentiated profiles that combine breadth across biomarkers and indications with durability and modality innovation. This may include extended dosing intervals enabled by long-acting or receptor-targeting approaches, inhaled delivery that supports earlier-line use, or bispecific and multi-specific strategies aimed at improving response rates. In this context, differentiation will hinge less on mechanism and more on delivering measurable advantages in convenience and clinical utility that align with how respiratory disease is actually managed. As these readouts unfold, TSLP inhibition is increasingly emerging not simply as another biologic class but as a potential backbone strategy in respiratory treatment.
About The Author:
Mercedes Fleming, Ph.D., is a senior business analyst at Lifescience Dynamics in London. She earned a doctorate in cancer biology from the Institute of Cancer Research in London before transitioning to work in biopharma consulting. She has supported clients across several indications, including respiratory diseases, bringing expertise in competitive intelligence.